November 29, 2022
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
November 28, 2022
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
November 21, 2022
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 16, 2022
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
November 10, 2022
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
November 9, 2022
Athira Pharma to Present at Stifel 2022 Healthcare Conference
November 7, 2022
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
October 17, 2022
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
September 6, 2022
Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
August 15, 2022
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Displaying 51 - 60 of 139